Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia

被引：87

作者：

Al Shweiki, M. H. D. Rami ^{[1
]}

Steinacker, Petra ^{[1
]}

Oeckl, Patrick ^{[1
]}

Hengerer, Bastian ^{[2
]}

Danek, Adrian ^{[3
]}

Fassbender, Klaus ^{[4
]}

Diehl-Schmid, Janine ^{[5
]}

Jahn, Holger ^{[6
]}

Anderl-Straub, Sarah ^{[1
]}

Ludolph, Albert C. ^{[1
]}

Schoenfeldt-Lecuona, Carlos ^{[7
]}

Otto, Markus ^{[1
]}

机构：

[1] Ulm Univ, Dept Neurol, Ulm, Germany

[2] Boehringer Ingelheim Pharma GmbH & Co KG, CNS Dis Res, Biberach, Germany

[3] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany

[4] Saarland Univ, Dept Neurol, Med Ctr, Homburg, Germany

[5] Tech Univ Munich, Dept Psychiat, Munich, Germany

[6] Univ Med Ctr Hamburg, Dept Psychiat & Psychotherapy, Hamburg, Germany

[7] Univ Ulm, Dept Psychiat & Psychotherapy 3, Ulm, Germany

来源：

JOURNAL OF PSYCHIATRIC RESEARCH | 2019年 / 113卷

关键词：

Serum NFL; Psychiatric disorders; Depression; Schizophrenia; Bipolar; bvFTD; Frontotemporal dementia; Simoa; Biomarker; CEREBROSPINAL-FLUID; DIAGNOSIS; PROTEIN; DISEASE;

D O I：

10.1016/j.jpsychires.2019.03.019

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

The overlapping symptoms of behavioural variant frontotemporal dementia (bvFTD) and primary psychiatric disorders (such as depressive disorder, schizophrenia spectrum, and bipolar disorder) present a challenge for the differential diagnosis of bvFTD in middle and older-aged people. Neurofilaments are cytoskeletal proteins in the neurons, and several studies have reported elevated levels of neurofilament light chain (NfL) in cerebrospinal fluid of neurodegenerative as well as psychiatric disorders. The study aims to determine the utility of serum NfL levels as a biomarker to differentiate between bvFTD and psychiatric disorder. In our study, we investigated the levels of NfL in the serum of schizophrenia (n = 11), depression (n = 28), bipolar (n = 11), bvFTD (n = 20) patients and controls (n = 27) by single molecule array (Simoa) technology. The schizophrenia, depression and bipolar patients did not show significant changes in serum NfL levels in comparison to the control group (p > 0.99). The serum NfL levels were significantly elevated in bvFTD patients in comparison to the control cohort (p < 0.0001), depression (p < 0.0001), schizophrenia (p < 0.0002) and bipolar patients (p < 0.0083). We propose serum NfL as a biomarker to differentiate bvFTD from psychiatric disorders and to rule out neurodegeneration in the course of psychiatric disorders.

引用

页码：137 / 140

页数：4

共 18 条

[1] Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies [J].